Predict your next investment

HEALTHCARE | Biotechnology
cellvir.com

See what CB Insights has to offer

Stage

Acquired | Acquired

Total Raised

$3.11M

About Cellvir

Developer of anti-retroviral treatments focused on the human immunodeficiency virus type 1 (HIV-1). The company's approach targets host-virus protein-protein interactions which have been shown to be essential for viral replication in infected cells. Drugs operating via this mode of action are hoped to offer two advantages: complementarity to existing drugs because of their lack of susceptibility to cross-resistance mechanisms and a reduced occurrence of viral mutations that lead to drug resistance. Although the current program of research is focused on HIV-1, the technologies developed to fight AIDS are applicable to other emergent virally caused diseases such as the hepatitis C virus (HCV), severe acute respiratory syndrome (SARS), or Avian Flu.

Cellvir Headquarter Location

4 rue Pierre Fontaine Pepiniere Genopole Entreprise

Evry, 91000,

France

33 1 60 87 89 00

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Cellvir Patents

Cellvir has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/26/2004

7/27/2010

Molecular biology, HIV/AIDS, Proteins, RNA, DNA

Grant

Application Date

5/26/2004

Grant Date

7/27/2010

Title

Related Topics

Molecular biology, HIV/AIDS, Proteins, RNA, DNA

Status

Grant

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.